跳至主要内容
临床试验/EUCTR2007-003976-20-IT
EUCTR2007-003976-20-IT进行中(未招募)不适用

A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following third molar tooth extraction. - ND

GLENMARK PHARMACEUTICALS SA0 个研究点开始时间: 2007年10月16日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Male and female patients (18-50 years of age), previously scheduled for extraction of at
  • least one 3rd impacted mandibular molar tooth under local anaesthesia, and who are
  • otherwise healthy, will be recruited.
  • -females of childbearing
  • potential must be using adequate contraception.
  • -Patient complaining of moderate to severe pain on Verbal Rating Scale (VRS)
  • within 3 hours after the end of surgery.
  • -Patient agreeing not to take analgesics other than protocol defined rescue
  • analgesics during treatment period (up to 24 hrs post dose).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Patient who has a history or presence of significant organ disease or mental
  • -Patient who has been exposed to analgesics within 24 hours prior to the start of surgery.
  • -Patient who is unable to refrain from alcohol, psychoactive drugs, and sedatives
  • (e.g. benzodiazepines) within 48 hours prior from the start of surgery and for 48hrs post dose.
  • -Patient who is judged by the investigator not to be a suitable candidate for
  • ibuprofen or co-efferalgan therapy based on medical history;
  • -Patient has a history of drug or alcohol abuse. Abuse of alcohol is defined as an
  • average weekly intake of greater than 21 units or an average daily intake of
  • greater than three units for males and intake greater than 14 units per week or an
  • average daily intake of greater than two units for females.
  • -History of sensitivity to any of the study medications, or components or a history
  • -Has a supine systolic blood pressure which is outside the range of 90 to 140
  • mmHg, supine diastolic blood pressure is outside the range of 50 to 90 mmHg or
  • supine heart rate is outside the range 45-100 bpm.
  • -QTc interval ≥450ms,a family history of Long QT syndrome, the use of concomitant medications that prolong the QT/QTc interval.

研究者

发起方
GLENMARK PHARMACEUTICALS SA

相似试验

进行中(未招募)
不适用
A randomized, double blind, placebo and active controlled, parallel groupstudy to evaluate the safety and efficacy of 6-week treatment with oral doses of50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in steroid-naïvepatients with persistent asthma
EUCTR2010-023326-20-LVBoehringer Ingelheim RCV GmbH & Co KG390
进行中(未招募)
不适用
A randomized, double blind, placebo and active controlled, parallel groupstudy to evaluate the safety and efficacy of 6-week treatment with oral doses of50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in steroid-naïvepatients with persistent asthma
EUCTR2010-023326-20-EEBoehringer Ingelheim RCV GmbH & Co KG390
进行中(未招募)
1 期
A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushesVasomotor symptoms (hot flushes)
EUCTR2007-001791-36-GBBayer Schering Pharma AG
进行中(未招募)
不适用
A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushes
EUCTR2007-001791-36-NLBayer Schering Pharma AG112
进行中(未招募)
不适用
A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushes
EUCTR2007-001791-36-DEBayer Schering Pharma AG118